Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study

Longer Term Efficacy of Lanreotide Autogel/Depot (LAN) for Symptomatic Treatment of Carcinoid Syndrome (CS) in Neuroendocrine Tumor (NET) Patients from the ELECT Open Label Study Meeting Abstract

authors

Vinik, Aaron I.

publication date

October 1, 2016

webpage

Web of Science

published in

AMERICAN JOURNAL OF GASTROENTEROLOGY Journal

start page

S457

end page

S458

volume

111